| Year |
Citation |
Score |
| 2020 |
Sun Y, Meyers BA, Czako B, Leonard P, Mseeh F, Harris AL, Wu Q, Johnson S, Parker CA, Cross JB, Di Francesco ME, Bivona BJ, Bristow CA, Burke JP, Carrillo CC, et al. Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib. Cancer Research. PMID 32928921 DOI: 10.1158/0008-5472.Can-20-1634 |
0.301 |
|
| 2019 |
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine. 11. PMID 31068440 DOI: 10.1126/Scitranslmed.Aau1167 |
0.317 |
|
| 2019 |
Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine. 11. PMID 30996079 DOI: 10.1126/Scitranslmed.Aav0936 |
0.312 |
|
| 2019 |
Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, et al. Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. Cell Reports. 26: 469-482.e5. PMID 30625329 DOI: 10.1016/J.Celrep.2018.12.043 |
0.321 |
|
| 2019 |
Echeverria G, Ge Z, Seth S, Jeter-Jones S, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, et al. Abstract GS5-05: Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Gs5-05 |
0.324 |
|
| 2019 |
Sun Y, Meyers BA, Johnson SB, Harris AL, Czako B, Cross JB, Leonard PG, Mseeh F, Francesco MED, Parker CA, Wu Q, Bristow CA, Burke JP, Carrillo CC, Carroll CL, et al. Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C036 |
0.335 |
|
| 2018 |
Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine. PMID 29892070 DOI: 10.1038/S41591-018-0052-4 |
0.322 |
|
| 2018 |
Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, et al. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nature Medicine. PMID 29892061 DOI: 10.1038/S41591-018-0019-5 |
0.317 |
|
| 2018 |
Zhang L, Zhang H, Guo H, Sun Y, Feng N, Marszalek JR, Ahmed M, Nomie K, Wang M. A Novel Patient-Derived Xenograft Model of Secondary CD20- CNS Lymphoma for Mechanistic and Therapeutic Exploration Blood. 132: 1669-1669. DOI: 10.1182/Blood-2018-99-112205 |
0.3 |
|
| 2018 |
Marszalek JR, Seth S, Corti D, Zhang Q, Echeverria GV, Han L, Sun Y, Molina J, Gera S, Chang E, Khor TO, Mahendra M, Feng N, McAfoos T, Giuliani V, et al. Abstract 2856: Targeting OXPHOS with IACS-010759 to eliminate standard of care resistant tumor cells Cancer Research. 78: 2856-2856. DOI: 10.1158/1538-7445.Am2018-2856 |
0.336 |
|
| 2018 |
Echeverria GV, Seth S, Ge Z, Carugo A, Bristow C, Mundi P, Jeter-Jones S, Zhang X, Zhou X, McCoy A, Cai S, Tu Y, Sun Y, Marszalek J, Califano A, et al. Abstract 212: High-resolution barcoding in patient-derived xenografts of triple-negative breast cancer reveals reversible chemoresistance conferred by non-mutational mechanisms Cancer Research. 78: 212-212. DOI: 10.1158/1538-7445.Am2018-212 |
0.324 |
|
| 2018 |
Francesco MED, Marszalek JR, McAfoos T, Carroll CL, Kang Z, Liu G, Theroff JP, Bardenhager JP, Bandi ML, Molina JR, Gera S, Protopopova M, Sun Y, Do MKG, Feng N, et al. Abstract 1655: Discovery and development of IACS-010759, a novel inhibitor of Complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors Cancer Research. 78: 1655-1655. DOI: 10.1158/1538-7445.Am2018-1655 |
0.33 |
|
| 2017 |
Lin Y, Satani N, Hammoudi N, Pisaneschi F, Leonard P, Maxwell D, Peng Z, Link T, Gilbert LIR, Bosajou A, Sun D, Marszalek J, Sun Y, McMurray JS, Mandal PK, et al. Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A39 |
0.329 |
|
| 2017 |
Molina J, Bandi M, Bardenhagen J, Bristow C, Carroll C, Chang E, Cross J, Daver N, Feng N, Do MG, Greer J, Han J, Hirst J, Huang S, Jiang Y, ... ... Sun Y, et al. Abstract 4971: IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors Cancer Research. 77: 4971-4971. DOI: 10.1158/1538-7445.Am2017-4971 |
0.353 |
|
| 2017 |
Giuliani V, Vangamudi B, Suzuki E, Miller M, Liu C, Carugo A, Bristow C, Gao G, Han J, Sun Y, Feng N, Chang E, Marszalek J, Kovacs J, Francesco MED, et al. Abstract 3016: Identification of protein arginine methyltransferase 1 as novel epigenetic vulnerability in KRAS/p53 mutant PDAC primary patient models Cancer Research. 77: 3016-3016. DOI: 10.1158/1538-7445.Am2017-3016 |
0.318 |
|
| 2016 |
Liu Y, Bell T, Zhang H, Sun Y, Li CJ, Feng N, Huang S, Guo H, Wang J, Ahmed M, Zhang V, Lam LT, Nomie K, Zhang L, Di Francesco ME, et al. Targeting Oxphos Pathway Against Ibrutinib Resistance to Mantle Cell Lymphoma Blood. 128: 290-290. DOI: 10.1182/Blood.V128.22.290.290 |
0.313 |
|
| 2016 |
Protopopova M, Bandi M, Sun Y, Bardenhagen J, Bristow C, Carroll C, Chang E, Feng N, Do MG, Greer J, Konopleva M, Matre P, Kang Z, Liu G, Muller F, et al. Abstract A65: IACS-10759: A novel OXPHOS inhibitor that selectively kills tumors with metabolic vulnerabilities Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A65 |
0.354 |
|
| 2016 |
Lin Y, Satani N, Hammoudi N, Marszalek J, Sun Y, Protopopova M, Francesco MED, Czako B, Wang A, DePinho RA, Muller FL. Abstract 3837: Passenger deletion of ENO1 as a collateral lethality target in cancer Cancer Research. 76: 3837-3837. DOI: 10.1158/1538-7445.Am2016-3837 |
0.342 |
|
| 2015 |
Ablikim M, Achasov MN, Ai XC, Albayrak O, Albrecht M, Ambrose DJ, Amoroso A, An FF, An Q, Bai JZ, Ferroli RB, Ban Y, Bennett DW, Bennett JV, Bertani M, ... Sun YJ, ... Sun YZ, et al. Observation of a Neutral Structure near the DD[over ¯]^{*} Mass Threshold in e^{+}e^{-}→(DD[over ¯]^{*})^{0}π^{0} at sqrt[s]=4.226 and 4.257 GeV. Physical Review Letters. 115: 222002. PMID 26650295 DOI: 10.1103/Physrevlett.115.222002 |
0.479 |
|
| 2015 |
Ablikim M, Achasov MN, Ai XC, Albayrak O, Albrecht M, Ambrose DJ, Amoroso A, An FF, An Q, Bai JZ, Baldini Ferroli R, Ban Y, Bennett DW, Bennett JV, Bertani M, ... Sun YJ, ... Sun YZ, et al. Measurement of the Absolute Branching Fraction for Λ_{c}^{+}→Λe^{+}ν_{e}. Physical Review Letters. 115: 221805. PMID 26650293 DOI: 10.1103/Physrevlett.115.221805 |
0.477 |
|
| 2015 |
Zheng YL, Sun YP, Zhang H, Liu WJ, Jiang R, Li WY, Zheng YH, Zhang ZG. Mesenchymal Stem Cells Obtained from Synovial Fluid Mesenchymal Stem Cell-Derived Induced Pluripotent Stem Cells on a Matrigel Coating Exhibited Enhanced Proliferation and Differentiation Potential. Plos One. 10: e0144226. PMID 26649753 DOI: 10.1371/journal.pone.0144226 |
0.375 |
|
| 2015 |
Yang H, Sun Y, Yao F, Yu K, Gu H, Han B, Zhao H. Surgical Therapy for Bilateral Multiple Primary Lung Cancer. The Annals of Thoracic Surgery. PMID 26602007 DOI: 10.1016/j.athoracsur.2015.09.028 |
0.315 |
|
| 2015 |
Chen Y, Zheng YL, Qiu DB, Sun YP, Kuang SJ, Xu Y, He F, Gong YH, Zhang ZG. An extracellular matrix culture system for induced pluripotent stem cells derived from human dental pulp cells. European Review For Medical and Pharmacological Sciences. 19: 4035-46. PMID 26592825 |
0.377 |
|
| 2015 |
Ablikim M, Achasov MN, Ai XC, Albayrak O, Albrecht M, Ambrose DJ, Amoroso A, An FF, An Q, Bai JZ, Ferroli RB, Ban Y, Bennett DW, Bennett JV, Bertani M, ... Sun YJ, ... Sun YZ, et al. Observation of a Neutral Charmoniumlike State Z_{c}(4025)^{0} in e^{+}e^{-}→(D^{*}D[over ¯]^{*})^{0}π^{0}. Physical Review Letters. 115: 182002. PMID 26565461 DOI: 10.1103/Physrevlett.115.182002 |
0.475 |
|
| 2015 |
Protopopova M, Bandi M, Bardenhagen J, Bristow C, Carroll C, Chang E, Feng N, Do MG, Greer J, Konopleva M, Matre P, Kang Z, Liu G, Muller F, Lofton T, ... ... Sun Y, et al. Abstract 4455: Relapsed/refractory AML responds robustly to IACS-10759, a novel OXPHOS inhibitor Cancer Research. 75: 4455-4455. DOI: 10.1158/1538-7445.Am2015-4455 |
0.333 |
|
| 2015 |
Protopopova M, Bandi M, Bardenhagen J, Bristow C, Carroll C, Chang E, Feng N, Do MG, Greer J, Konopleva M, Matre P, Kang Z, Liu G, Muller F, Lofton T, ... ... Sun Y, et al. Abstract 4380: IACS-10759: A novel OXPHOS inhibitor which selectively kill tumors with metabolic vulnerabilities Cancer Research. 75: 4380-4380. DOI: 10.1158/1538-7445.Am2015-4380 |
0.337 |
|
| 2015 |
Lin Y, Marszalek J, Sun Y, Hammoudi N, Leonard P, Maxwell D, Satani N, Zhang P, Link T, Lee G, Francesco MED, Czako B, Want AY, DePinho RA, Muller FL. Abstract C183: Pomhex: a cell-permeable high potency Enolase inhibitor with in vivo anti-neoplastic activity Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C183 |
0.356 |
|
| Show low-probability matches. |